SCHEMBL18919111

SCHEMBL18919111

COc1ccc2[nH]c(C)c(/C=C/C(=O)N3CCN(CCc4ccc(F)cc4)CC3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PIKFYVE Q9Y2I7 1/20 0.48
▸ MAPT P10636 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ACHE P22303 2/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ GPR183 P32249 2/20 0.43
▸ HTR1A P08908 2/20 0.42
▸ GSK3B P49841 2/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ABCC1 P33527 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ CDK2 P24941 1/20 0.41
▸ CDK16 Q00536 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16739358 1.00 PIKFYVE (0.48) PIKFYVEMAPTKDM4EACHEKMT2A
SCHEMBL18919161 0.95 PIKFYVE (0.51) PIKFYVEMAPTKDM4EACHEKMT2A
SCHEMBL18919163 0.95 PIKFYVE (0.51) PIKFYVEMAPTKDM4EACHEKMT2A
SCHEMBL18919206 0.91 PIKFYVE (0.49) PIKFYVEMAPTKDM4EACHEKMT2A
SCHEMBL18919203 0.91 PIKFYVE (0.49) PIKFYVEMAPTKDM4EACHEKMT2A
SCHEMBL18919156 0.91 ACHE (0.47) PIKFYVEMAPTKDM4EACHEKMT2A
SCHEMBL18919158 0.91 ACHE (0.47) PIKFYVEMAPTKDM4EACHEKMT2A
SCHEMBL18919117 0.89 SIGMAR1 (0.54) PIKFYVEMAPTACHEKMT2AGPR183
SCHEMBL18919115 0.89 SIGMAR1 (0.54) PIKFYVEMAPTACHEKMT2AGPR183
SCHEMBL18919089 0.86 RXFP1 (0.48) PIKFYVEMAPTKDM4EKMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170157135-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS NOVOGEN LIMITED (AU) 2017-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170157135-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS TPM3, TPM4, TNNI3 PIKFYVE 1833/4885MAPT 2167/4885KDM4E 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback